The statistical design and analysis of pandemic platform trials: Implications for the future

The Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) Cross-Trial Statistics Group gathered lessons learned from statisticians responsible for the design and analysis of the 11 ACTIV therapeutic master protocols to inform contemporary trial design as well as preparation for a futu...

Full description

Saved in:
Bibliographic Details
Published in:Journal of clinical and translational science 2024, Vol.8 (1), p.e155, Article e155
Main Authors: Lindsell, Christopher J, Shotwell, Matthew, Anstrom, Kevin J, Berry, Scott, Brittain, Erica, Harrell, Frank E, Geller, Nancy, Grund, Birgit, Hughes, Michael D, Jagannathan, Prasanna, Leifer, Eric, Moser, Carlee B, Price, Karen L, Proschan, Michael, Stewart, Thomas, Thomas, Sonia, Touloumi, Giota, LaVange, Lisa
Format: Article
Language:English
Subjects:
Clinical trials
COVID-19
COVID-19 Therapeutic Platform Trials Lessons Learned
Design
Hospitalization
Mortality
pandemic preparedness
Pandemics
platform trials
research design
Special Communication
Statistical analysis
Statistics
Teams
Therapeutic applications
Working groups
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) Cross-Trial Statistics Group gathered lessons learned from statisticians responsible for the design and analysis of the 11 ACTIV therapeutic master protocols to inform contemporary trial design as well as preparation for a future pandemic. The ACTIV master protocols were designed to rapidly assess what treatments might save lives, keep people out of the hospital, and help them feel better faster. Study teams initially worked without knowledge of the natural history of disease and thus without key information for design decisions. Moreover, the science of platform trial design was in its infancy. Here, we discuss the statistical design choices made and the adaptations forced by the changing pandemic context. Lessons around critical aspects of trial design are summarized, and recommendations are made for the organization of master protocols in the future.
ISSN:2059-8661
2059-8661
DOI:10.1017/cts.2024.514